Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting [Yahoo! Finance]
Erasca, Inc. (ERAS)
Company Research
Source: Yahoo! Finance
Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and preliminary FLAGSHP-1 Phase 1 results for ERAS-601 and cetuximab in chordoma SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present one oral presentation and two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois. The abstracts will be available on the ASCO meeting website. The posters will be available online at Erasca.com/events/presentations following the presentations. Presentation Details Abstract 3517 - Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V60
Show less
Read more
Impact Snapshot
Event Time:
ERAS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERAS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERAS alerts
High impacting Erasca, Inc. news events
Weekly update
A roundup of the hottest topics
ERAS
News
- Erasca Announces Three Presentations at the 2024 ASCO Annual MeetingGlobeNewswire
- Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock? [Yahoo! Finance]Yahoo! Finance
- Institutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year losses [Yahoo! Finance]Yahoo! Finance
- Erasca, Inc. (NASDAQ: ERAS) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $6.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
ERAS
Earnings
- 3/27/24 - Beat
ERAS
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- ERAS's page on the SEC website